Comparative effectiveness of budesonide EC and telitacicept in proteinuria and eGFR trajectories in IgA nephropathy: a retrospective cohort study - Takeaways - MDSpire

Comparative effectiveness of budesonide EC and telitacicept in proteinuria and eGFR trajectories in IgA nephropathy: a retrospective cohort study

  • By

  • Xingsheng Zuo

  • Yaqin Wang

  • Fangfang Ma

  • Xianyuan Zhu

  • Chenglong Zhao

  • May 13, 2026

Share

  • 1

    IgA nephropathy (IgAN) is the most common primary glomerulonephritis, with significant global incidence variation, particularly high in East Asia.

  • 2

    This study compared the efficacy of budesonide EC and telitacicept in reducing proteinuria and maintaining eGFR in patients with IgAN.

  • 3

    Telitacicept showed a greater reduction in proteinuria, especially in patients with mild-to-moderate baseline proteinuria.

  • 4

    Budesonide EC was associated with a higher average eGFR during follow-up, but this significance diminished after propensity score matching.

  • 5

    The findings highlight the need for further prospective studies to validate the comparative effectiveness of these treatments in IgAN.

Original Source(s)

Comparative effectiveness of budesonide EC and telitacicept in proteinuria and eGFR trajectories in IgA nephropathy: a retrospective cohort study

  • by Xingsheng Zuo, Yaqin Wang, Fangfang Ma, Xianyuan Zhu, Chenglong Zhao

  • May 13, 2026

Related Content

7 Days Noninferior in Bacteremia

BALANCE compared 7 vs 14 days of treatment among hospitalized patients with bloodstream infections.

FDA Clears AI Sepsis Warning System

An FDA-cleared AI tool developed at Johns Hopkins detects sepsis up to 48 hours earlier than clinicians — and has cut related deaths by 18%.

How Social Contact Shapes Gut Microbes

Cooperative behavior linked to shared anaerobic gut bacteria

  • May 11, 2026

  • 2 min